FTO-IN-17
Based on 1 Customer Validation
FTO-IN-17 is an orally active and brain-penetrant FTO (m6A RNA demethylase) inhibitor with an IC50 of 1.1 μM. FTO-IN-17 stably binds the FTO catalytic pocket. FTO-IN-17 protects against Aβ1-42-induced toxicity while increasing global m6A levels and dampening pro-inflammatory gene (CXCL10, TNF-α) expression. FTO-IN-17 ameliorates anxiety-like behavior and rescues hippocampal-dependent spatial, recognition memory and neuroinflammation in Alzheimer's disease mice models.
For research use only. We do not sell to patients.
- Purity : 99.38%
- CAS No.: 1434867-98-7
- Formula: C20H23FN4O2
- Molecular Weight:370.42
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Biological Activity
Description
In Vitro
FTO-IN-17 (Compound VI) exhibits high in vitro blood-brain barrier permeability (Pe = 12.2 × 10-6 cm/s)[1].
FTO-IN-17 (0.01-50 μM; overnight) potently inhibits human FTO demethylase activity with an IC50 of 1.1 μM[1].
FTO-IN-17 (10 μM; overnight) is fully selective for human FTO over human ALKBH5 demethylase, showing no inhibition of ALKBH5 at 10 μM[1].
The (S)-stereoisomer of FTO-IN-17 exhibits significantly stronger, more stable binding to human FTO than the (R)-stereoisomer, with over 7 times higher calculated binding affinity[1].
FTO-IN-17 (0.001-50 μM; 30 min pre-incubation + 24 h co-incubation) provides sustained, dose-dependent neuroprotection against Aβ1-42-induced toxicity in differentiated SH-SY5Y cells, increases global m6A levels, and downregulates pro-inflammatory gene expression at 1 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:differentiated SH-SY5Y human neuroblastoma cells
-
Concentration:0.001, 0.01, 0.1, 1, 10, 50 μM
-
Incubation Time:30 min pre-incubation, followed by 24 h co-incubation with 5 μM Aβ1-42
-
Result:Demonstrated dose-dependent neuroprotection, with 70-85% cell viability at 0.1-10 μM.
Significantly increased global m6A RNA methylation levels compared to Aβ1-42-treated cells at 1 μM.
Significantly downregulated mRNA expression of pro-inflammatory genes CXCL10, TNF-α, and HMOX1 at 1 μM.
Parmacokinetics
| Species | Dose | Route | Cmax | Tmax | Cmax (Brain) | Tmax (Brain) | Brain-Kp |
|---|---|---|---|---|---|---|---|
| Mice[1] | 3 mg/kg | p.o. | 51.3 ng/mL | 5 min | 29.9 ng/g | 5 min | 58 % |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Alzheimer's disease model (SAMP8, 5-month-old female; sporadic Alzheimer's disease model)[1]
-
Dosage:3 mg/kg
-
Administration:p.o.; daily; 28 days
-
Result:Significantly reduced anxiety-like behavior via decreased rearing and grooming in the open field test.
Rescued hippocampal-dependent spatial memory, with object location test discrimination index recovered to levels comparable to SAMR1 control mice.
Significantly increased both short-term and long-term recognition memory relative to SAMP8 control mice via novel object recognition test discrimination indices.
Increased global m6A methylation levels in brain tissue.
Upregulated expression of synaptic plasticity genes Arc and Egr1 in brain tissue.
Downregulated expression of neuroinflammatory genes Cxcl10, iNOS, and Hmox1 in brain tissue.
Chemical Information
-
CAS No. 1434867-98-7
-
Appearance Solid
-
Molecular Weight 370.42
-
Formula C20H23FN4O2
-
Color Light yellow to yellow
-
SMILES
CC(C1=NOC(C2CCCN(C2)CC3=NC4=C(C=CC=C4C(O)=C3)F)=N1)C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Solvent & Solubility
In Vitro:
DMSO : 25 mg/mL (67.49 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Protocol for Open Field Test (OF)
The Open Field Test is a rodent behavioral assay that measures spontaneous locomotion, exploratory behavior, and anxiety-like behavior when an animal is placed in a novel open arena. The main readouts are total distance traveled, movement time, velocity, center-zone entries, center-zone time, peripheral-zone time, and thigmotaxis. The assay is based on the conflict between exploration of a novel environment and avoidance of exposed open areas; higher center exploration is commonly interpreted as lower anxiety-like behavior, whereas increased wall-following or peripheral occupancy is interpreted as higher anxiety-like behavior.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Protocol for Elevated Plus Maze Test
The Elevated Plus Maze is a rodent anxiety-like behavior assay based on the conflict between spontaneous exploration and avoidance of open, elevated, exposed spaces. The apparatus contains two open arms and two closed arms arranged in a plus shape, and rodents normally spend more time in closed arms than open arms. The assay readout is generated by recording arm entries, time spent in open and closed arms, and related exploratory behaviors. Increased open-arm time or open-arm entries is commonly interpreted as reduced anxiety-like behavior, whereas reduced open-arm exploration is interpreted as increased anxiety-like behavior.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Alzheimer’s Disease Modeling
Alzheimer’s Disease (AD) is a neurodegenerative disorder characterized by a progressive decline in cognitive functions and loss of specific types of neurons and synapses. Alzheimer's symptoms can be simulated in mice by injecting drugs (such as Aβ) or genetically modified.
Purity & Documentation
-
Data Sheet (274 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6996 mL | 13.4982 mL | 26.9964 mL | 67.4910 mL |
| 5 mM | 0.5399 mL | 2.6996 mL | 5.3993 mL | 13.4982 mL | |
| 10 mM | 0.2700 mL | 1.3498 mL | 2.6996 mL | 6.7491 mL | |
| 15 mM | 0.1800 mL | 0.8999 mL | 1.7998 mL | 4.4994 mL | |
| 20 mM | 0.1350 mL | 0.6749 mL | 1.3498 mL | 3.3745 mL | |
| 25 mM | 0.1080 mL | 0.5399 mL | 1.0799 mL | 2.6996 mL | |
| 30 mM | 0.0900 mL | 0.4499 mL | 0.8999 mL | 2.2497 mL | |
| 40 mM | 0.0675 mL | 0.3375 mL | 0.6749 mL | 1.6873 mL | |
| 50 mM | 0.0540 mL | 0.2700 mL | 0.5399 mL | 1.3498 mL | |
| 60 mM | 0.0450 mL | 0.2250 mL | 0.4499 mL | 1.1248 mL |